Furthermore, both in in vitro and in vivo settings, CD44 expression was reported to promote the acquisition of sorafenib resistance by liver cancer cells once they had gained a mesenchymal-like transformation status as a result of persistent exposure to TGFβ27. The gene discussed is CD44; the disease is liver cancer.